Primary proinflammatory cytokines, such as IL-1b, play a crucial pathogenic role in multiple sclerosis and its animal model experimental autoimmune encephalomyelitis (EAE), and may represent, therefore, a suitable therapeutic target. We have previously established the delivery of anti-inflammatory cytokine genes within the central nervous system (CNS), based on intracisternal (i.c.) injection of non-replicative HSV-1-derived vectors. Here we show the therapeutic efficacy of i.c. administration of an HSV-1-derived vector carrying the interleukin-1receptor antagonist (IL-1ra) gene, the physiological antagonist of the proinflammatory cytokine IL-1, in C57BL/6 mice affected by myelin oligodendrocyte glycoprotein-induced EAE. IL-1ra gene therapy is effective preventively, delaying EAE onset by almost 1 week (22.471.4 days post-immunization vs 15.972.1 days in control mice; P ¼ 0.0229 log-rank test), and decreasing disease severity. Amelioration of EAE course was associated with a reduced number of macrophages infiltrating the CNS and in a decreased level of proinflammatory cytokine mRNA in the CNS, suggesting an inhibitory activity of IL-1ra on effector cell recruitment, as antigen-specific peripheral T-cell activation and T-cell recruitment to the CNS is unaffected. Thus, local IL-1ra gene therapy may represent a therapeutic alternative for the inhibition of immune-mediated demyelination of the CNS. Gene Therapy (2007) 14, 93-98.
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system (CNS) of unknown etiology. 1 The pathological hallmark of the disease is the presence within the CNS of inflammatory infiltrates containing few autoreactive T cells and many pathogenic non-CNS antigen-specific lymphocytes. 2 It is currently believed that antigen-specific T cells provide the organ specificity of the pathogenic process and regulate the recirculation within the CNS of nonspecific mononuclear cells, which in turn act as effector cells by releasing inflammatory myelinotoxic substances. 3 Proinflammatory cytokines are crucial in the development of the pathogenic process sustaining MS as they participate not only in antigen-specific T cell activation but also represent the main mediators of mononuclear cell activation in the periphery. 4 Tumor necrosis factor (TNF)-a, interferon (IFN)-g and interleukin (IL)-1b are present in demyelinating plaques. 5 In experimental autoimmune encephalomyelitis (EAE), an animal model for MS, IL-1b has been shown to be a mediator of the inflammatory process, 6 its peripheral levels correlate with the clinical course 7 and IL-1b reactivity has been shown during EAE in CNS-infiltrating macrophages and in resident microglial cells. 8 IL-1 receptor antagonist (IL-1ra) is a physiological inhibitor of IL-1, and its peripheral administration in EAE rats and mice before disease onset results in amelioration of the disease. [9] [10] [11] [12] IL-1b may represent, therefore, a suitable therapeutic target in MS. However, systemic delivery of antiinflammatory cytokines (IFN-b, TGF-b, TNF-a receptor p55) in MS patients has shown limited or no efficacy and considerable toxicity. [13] [14] [15] [16] This is possibly owing to the scarce ability of systemically administered cytokines to cross the blood-brain barrier (BBB) and accumulate in the CNS where the MS pathogenic process takes place, their short half-life and undesirable systemic side effects. [13] [14] [15] [16] The CNS delivery of anti-inflammatory cytokines could partially overcome these limitations.
We constructed an IL-1ra producing non-replicative Herpes simplex virus-1 (HSV-1) derived vector (TH:IL1ra) by inserting the IL-1ra expression cassette, constituted by the HCMV immediate-early promoter, the IL-1ra coding sequence and the bovine growth hormone polyA, by homologous recombination into the HSV-1 triple mutant TH:LAC-Z, lacking the immediate-early genes coding for infected cell polypeptide (ICP)4, ICP27 and ICP22. 17 Vectors were propagated on a complementing cell line (b7) as described previously. 17 HSV-1 stocks were diluted with complete Dulbecco's modified Eagle's media to obtain 1 Â 10 8 plaque-forming units (PFU)/ml. Naive C57BL/6 mice have been used to trace the nonreplicative HSV-1-derived vector distribution after intracisternal (i.c.) injection. Mice were killed 48 h after vector injection. As soon as 48 h after injection, the IL-1ra containing vector (TH:IL-1ra) distributed in all ventricular and subarachnoid spaces (Figure 1a) . Vectors Figure 1 Distribution and IL-1ra production in naive C57BL/6 mice injected with TH:IL-1ra. Each vector injection consisted in the delivery of 10 ml (1 Â 10 7 PFU) of the vectors within the cisterna magna (i.c.) of mice by using a 27 Ga stainless-needle curved (401) at 3.5 mm from the tip, so that it was J-shaped as described previously. 18 (a) For the detection of HSV-1, tissue sections were incubated with a rabbit anti-HSV-1 polyclonal antibody (Accurate, New York, NY, USA) and then to a biotinylated donkey anti-rabbit Ig antibody (Amersham, Buckinghamshire, UK) whose signal was amplified by an avidin-biotin complex (Vector, Burlingame, CA, USA). The TH:IL-1ra vector is detected within ependymal cells surrounding the fourth ventricle ( Â 20), but not in the surrounding brain parenchyma. (b) IL-1Ra levels in the CSF and serum 3 days after i.c. administration of 10 ml of the viral vector delivering IL-Ra (TH:IL-1ra) or the control vector (TH:Lac-Z). Serum data are the mean7s.e. of five mice, whereas for CSF measurements, samples have been pooled. CSF was withdrawn, after removal of neck, skin and muscles, by puncturing with a glass needle the tissue between the atlas vertebra and the occiput. Four to 8 ml of CSF were recovered from each animal. IL-1ra has been measured by a two-site ELISA kindly provided by S Poole (NIBSC, Potters Bar Herts, UK). Day of disease onset 9 9/9 13.370. HSV-1-mediated IL-1ra CNS gene therapy ameliorates EAE R Furlan et al efficiently infected choroidal, ependymal and leptomeningeal cells but did not reach the CNS parenchyma ( Figure 1a) . In mice treated with the TH:IL-1ra vector, IL-1ra protein was increased, as expected, in the cerebrospinal fluid (CSF) (1054 pg/ml) obtained 72 h after injection, compared to the control vector injected mice (35 pg/ml), but not in serum (265712 vs 224714 pg/ml in control mice) (Figure 1b) . IL-1ra production did not induce per se any pathological effect in the CNS. In order to test the therapeutic efficacy of the IL-1ra-producing HSV-1-derived vector in our CNS delivery model, we induced EAE in C57BL/6 mice by myelin oligodenrocyte glycoprotein (MOG) 35-55 immunization. Mice were injected i.c. with TH:IL-1ra the day of immunization and after 7 days. Mice injected with TH:LacZ following the same schedule were used as controls. Data presented are the sum of two independent experiments and are summarized in Table 1 . In mice treated with TH:IL-1ra, disease onset was significantly delayed (P ¼ 0.0229, long-rank test) as shown in Figure  2a and Table 1 . Furthermore, disease severity was significantly reduced (P ¼ 0.0008 Mann-Whitney; Figure  2b and Table 1) in TH:IL-1ra-treated mice as compared to control mice. On the other hand, when we treated MOG 35-55 -immunized C57BL/6 mice with TH:IL-1ra after disease onset, EAE progressed unaffected as compared to TH:LacZ-treated control mice (Table 1) .
We examined the CNS of EAE mice treated by IL-1ra gene therapy at the end of the clinical follow-up. Data are summarized in Table 2 . We found that TH:IL-1ra-injected mice had a significant decrease (Po0.0001 t-test) in the number of inflammatory foci in the spinal cord ( Figure  2c-d and Table 2 ), and a nonsignificant reduction in the areas of demyelination and axonal loss ( Table 2 ). When we examined the phenotype of CNS-infiltrating cells by immunohistochemistry, we found that, despite a comparable number of T cells entering the CNS, perimeningeal macrophages were significantly reduced (Po0.05 t-test) in EAE mice injected withTH:IL-1ra (Figure 2e-f and Table 2 ).
To verify if the clinical and neuropathological changes that we observed in TH:IL-1ra-treated EAE mice were owing to alterations of the peripheral immune system, we analyzed MOG 35-55 -specific T-cell reactivity in lymph nodes draining the immunization site. As shown in Figure 3a , MOG 35-55 specific T cell proliferation was not affected in TH:IL-1ra-treated mice compared to TH:LacZtreated controls. The same cells produced similar amounts of IFN-g (2023.3764.3 vs 16557184.53 pg/ml in control mice) and IL-4 (68.575.3 vs 48.476.5 pg/ml in control mice) in response to in vitro restimulation with 10 mM MOG 35-55 (Figure 3b-c) . These results suggest that the effect of the IL-1ra gene delivery to EAE mice was mainly owing to its in situ action in the CNS.
To investigate if the therapeutic effect observed after IL-1ra gene delivery in EAE mice was owing to the modulation of the local CNS cytokine milieu, C57BL/6 EAE mice injected with the TH:IL-1ra vector or the empty TH:LacZ control vector were killed 7 and 14 days after injection and semiquantitative RT-PCR was performed on the brain, spinal cord and blood samples for IL-1b, IL-6, TNF-a, and IFN-g. Naive C57BL/6 mice were used to determine baseline values. HSV-1-mediated IL-1ra gene delivery in the CNS induced a profound suppression, in the brain, of IL-1b (Figure 3d ), IL-6 (Figure 3e ), TNF-a (Figure 3f ) and IFN-g (Figure 3g ) mRNAs. Similar values were obtained in the spinal cord, whereas in the blood, proinflammatory cytokine mRNAs were unaffected (data not shown).
Cytokines are potentially useful candidate molecules for the therapy of immune-mediated CNS demyelination. Their use is, however, limited by their poor ability to cross the BBB and to reach the pathologically relevant site of action. We devised a CNS-targeted gene therapy approach based on the delivery of genes coding for soluble molecules in the cells of the ependymal and leptomeningeal layer. [18] [19] [20] [21] [22] [23] These cells release the product of the heterologous gene into the liquoral circulation from where the potentially therapeutic molecule can reach the brain parenchyma at multiple sites. The ability of this technique to target the brain in its entirety makes it an attractive alternative to systemic cytokine adminis- 
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tration. We and others have already described that interference with the IL-1-mediated inflammatory pathway, either using a specific inhibitor of IL-1 proteolytic activation or peripheral administration of IL-1ra, has a therapeutic effect on EAE in a preventive setting, but is ineffective if administered after disease onset. 7, 12 In the and murine air pouch. 30 In these reports, the protective effect of IL-1 inhibition was mostly related to decreased tissue destruction. Our study shows that IL-1ra CNS gene therapy was associated with a decreased number of macrophages infiltrating the CNS, although the number of infiltrating T cells appeared to be unaffected. The inhibition of the IL-1 signaling pathway might have induced a decrease in the ability of MOG 35-55 -specific T cells to deliver a chemoattractant environment in the CNS (i.e. decreased release of chemokines, decreased levels of adhesion molecules on the endothelium), thus possibly slowing down the recruitment of monocytic effector cells and delaying the appearance and decreasing severity of clinical signs of the disease. The decreased number of CNS-infiltrating macrophages can determine decreased levels of monocyte-related proinflammatory cytokine mRNA such as IL-1b, IL-6 and TNF-a, but is associated also to IFN-g decrease since IL-12 released by macrophages in turn induces IFN-g release from NK cells and cytotoxic T-lymphocytes in the CNS. 31 Once the chronic inflammatory process has started, however, disease maintenance mechanisms are independent from the IL-1 system, and interference with this pathway, by peripheral administration of caspase-1 inhibitors or IL-1ra, or releasing IL-1ra in situ, has no effect on disease course. Thus, in situ IL-1ra gene therapy mediated by non-replicative HSV-1-derived vectors has shown to be effective in the preventive treatment of chronic EAE and might represent a useful therapeutic alternative for the prevention of relapses in human MS, although limited by the short-term expression of the therapeutic gene by this generation of HSV-1-derived vectors.
